OPKO Health, Inc. (OPK)

NASDAQ: OPK · Real-Time Price · USD
1.540
-0.030 (-1.91%)
At close: Dec 20, 2024, 4:00 PM
1.560
+0.020 (1.30%)
After-hours: Dec 20, 2024, 5:43 PM EST
-1.91%
Market Cap 1.04B
Revenue (ttm) 711.41M
Net Income (ttm) -133.73M
Shares Out 672.80M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,228,248
Open 1.560
Previous Close 1.570
Day's Range 1.530 - 1.570
52-Week Range 0.850 - 1.760
Beta 1.63
Analysts Strong Buy
Price Target 2.75 (+78.57%)
Earnings Date Nov 7, 2024

About OPK

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers,... [Read more]

Sector Healthcare
IPO Date Nov 2, 1995
Employees 3,930
Stock Exchange NASDAQ
Ticker Symbol OPK
Full Company Profile

Financial Performance

In 2023, OPKO Health's revenue was $863.50 million, a decrease of -14.01% compared to the previous year's $1.00 billion. Losses were -$188.86 million, -42.49% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for OPK stock is "Strong Buy." The 12-month stock price forecast is $2.75, which is an increase of 78.57% from the latest price.

Price Target
$2.75
(78.57% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

NextPlat to Showcase OPKO Healthcare Products at the 2024 China International Natural Health & Nutrition Expo

OPKO Healthcare's Veterinary Care Products to be Introduced at Asia's Largest Health and Nutrition Tradeshow Company Invited to Present at Special Event Hosted by U.S. Consulate General During the Exp...

Other symbols: NXPL
4 weeks ago - PRNewsWire

NextPlat Reports $49.8 Million in Consolidated Revenue for the Nine Months Ended September 30, 2024, Representing a 136% Increase Over 2023 Results

Company Sees Initial Sales Momentum in China for OPKO Health Products as it Prepares for the Launch of its Florida Sunshine Brand of Vitamins and Supplements COCONUT GROVE, Fla. , Nov. 14, 2024 /PRNew...

Other symbols: BABANXPL
5 weeks ago - PRNewsWire

OPKO Health, Inc. (OPK) Q3 2024 Earnings Conference Call Transcript

OPKO Health, Inc. (NASDAQ:OPK) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Yvonne Briggs - Alliance Advisor, IR Phillip Frost - Chairman and CEO Elias Zerhouni -...

6 weeks ago - Seeking Alpha

ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program

WESTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ: OPK) company, announces it has been awarded $35 million of additional funding under an existing ...

2 months ago - GlobeNewsWire

NextPlat Secures Four-Year Extension of OPKO Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan

Company to Support the Sales and Marketing of OPKO's Products on Additional E-Commerce Platforms and on Social Media Channels in China and into the Large Japanese Health and Wellness Market COCONUT GR...

Other symbols: NXPL
2 months ago - PRNewsWire

Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health

Enhances Labcorp's laboratory services network and expands access to its clinical services  BURLINGTON, N.C. and MIAMI , Sept.

Other symbols: LH
3 months ago - PRNewsWire

OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results

MIAMI, Aug. 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2024. Highlights from the second ...

4 months ago - GlobeNewsWire

OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA's Profit Share Payments

MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPK...

5 months ago - GlobeNewsWire

OPKO Health to Participate in the Jefferies Global Healthcare Conference

MIAMI, May 31, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Global Healthcare Conference, being held June 4-6, 2024 a...

7 months ago - GlobeNewsWire

OPKO Health, Inc. (OPK) Q1 2024 Earnings Call Transcript

Start Time: 16:30 January 1, 0000 5:21 PM ET OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Conference Call May 07, 2024, 16:30 PM ET Company Participants Phil Frost - Chairman and CEO Elias Zerhoun...

8 months ago - Seeking Alpha

OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results

MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024. First quarter business highlights i...

8 months ago - GlobeNewsWire

OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024

MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial ...

8 months ago - GlobeNewsWire

Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business

Transaction to enhance Labcorp's laboratory services network  and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 28, 2024 /PRNewswire/ -- L...

Other symbols: LH
9 months ago - PRNewsWire

AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans • Candidate showed similar half-life to standard monoclonal antibo...

10 months ago - GlobeNewsWire

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

OPKO Health, Inc. (OPK) Q4 2023 Earnings Call Transcript

10 months ago - Seeking Alpha

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights from...

10 months ago - GlobeNewsWire

OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S....

10 months ago - GlobeNewsWire

OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser's Option to Purchase Additional Notes

MIAMI, Jan. 09, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the closing of its previously announced private offering of $230.0 million aggregate principal ...

1 year ago - GlobeNewsWire

OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 Proceeds to be used for privately negotiated repurchases of common stoc...

1 year ago - GlobeNewsWire

OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Proceeds to be used for privately negotiated repurchases of common stock and outstanding 4.50% Convertible Senior Notes due 2025 Proceeds to be used for privately negotiated repurchases of common stoc...

1 year ago - GlobeNewsWire

BioReference Health and Prognos Health Collaborate to Advance Precision Medicine and Testing

ELMWOOD PARK, N.J. , Nov. 28, 2023 /PRNewswire/ -- BioReference® Health, LLC (BRH), a leading specialty laboratory in the United States, announced a strategic collaboration with Prognos Health, a pion...

1 year ago - PRNewsWire

BioReference® Signs On as the First Laboratory to Use MSK-ACCESS® Powered with SOPHiA DDM™

World-class liquid biopsy testing will be made commercially available to BioReference® customers across the country BOSTON and ELMWOOD PARK, N.J. and ROLLE, Switzerland , Nov. 7, 2023 /PRNewswire/ -- ...

Other symbols: SOPH
1 year ago - PRNewsWire

OPKO Health, Inc. (OPK) Q3 2023 Earnings Call Transcript

OPKO Health, Inc. (NASDAQ:OPK) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Phillip Frost - Chairman and Chief Executive Of...

1 year ago - Seeking Alpha

OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

MIAMI, Nov. 06, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2023. Business highlights f...

1 year ago - GlobeNewsWire

New Clinical Data on OPKO Health's RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (AS...

1 year ago - GlobeNewsWire